The following is a summary of the Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript:
Financial Performance:
Pulmonx reported a total worldwide revenue of $20.4 million for Q3, up 15%
U.S. revenue grew by 17% year-over-year, while international revenue increased by 12%
Gross margin maintained at 74%, despite changes in geographic mixReduced net loss to $14.1 million from $14.9 million in the same quarter last year
Business Progress:
Implemented strategic commercial pillars leading to 280 active Zephyr Valve accounts across the U.S
Launched LungTraX Platform pilot, a diagnostic tool aimed at streamlining patient workflows and identifying eligible patients
Expanded international operations, particularly through new distributor relationships in China and ongoing European engagements
Advanced clinical trials for AeriSeal system with promising data, supporting future commercial availability
Opportunities:
The international revenue growth, particularly with contributions from a new distributor in China, indicates expanding global market presence
Potential growth opportunities from the LungTraX platform once fully deployed in customer centers
Risks:
Seasonality impacts observed in Q3, could pose risks if similar patterns affect future quarters
Integration and adoption delays for LungTraX Platform could affect expected benefits and revenue from this technology
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
